<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75570">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939444</url>
  </required_header>
  <id_info>
    <org_study_id>OPI-12-001</org_study_id>
    <secondary_id>2012-004989-18</secondary_id>
    <nct_id>NCT01939444</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Bioavailability of Nasal Naloxone</brief_title>
  <official_title>A Pilot Study of the Bioavailability of Nasal Naloxone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iceland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall is aim of this pilot study is to give a preliminary estimation of key parameters
      of the pharmacokinetics of a proper formulation of intranasal naloxone. These data will be
      used to design a well justified protocol for the final estimation of these parameters:

        -  Preliminary estimation of bioavailability of this intranasal naloxone in human, healthy
           volunteers

        -  Preliminary estimation of the maximum serum concentration (Cmax) of this formulation

        -  Preliminary estimation of  the time to maximum serum concentration (Tmax) of this
           formulation

        -  Safety of the formulation
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>preliminary bioavailability of nasal naloxone</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measured as ratio of area under the time concentration curve for nasal over intravenous naloxone x 100. Plasma concentration data will be analyzed by non-compartmental techniques.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to maximum concentrations</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum concentration</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Drug Overdose</condition>
  <arm_group>
    <arm_group_label>naloxone intranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg by the nasal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naloxone intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone intranasal</intervention_name>
    <description>If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally</description>
    <arm_group_label>naloxone intranasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone intravenous</intervention_name>
    <description>The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position</description>
    <arm_group_label>naloxone intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy (adequate organ function is determined by electrocardiogram (ECG), liver and
             kidney clinical chemistry, and a standard clinical examination/interview. For safety
             reasons we may ask for urine sample for analysis of opioids)

          -  informed consent

        Exclusion Criteria:

          -  history of liver disease

          -  taking any medications including herbal medicines the last week history of drug abuse

          -  any local nasal disease or nasal surgery or recent cold for the last week

          -  any history of drug allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ã˜yvind Ellingsen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of circulation and medical imaging, NTNU</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antidotes</keyword>
  <keyword>naloxone</keyword>
  <keyword>administration, intravenous</keyword>
  <keyword>administration, intranasal</keyword>
  <keyword>pharmacology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
